rhenium-186-chelated nanoliposome
plus therapeutics,plus theraputics
['rhenium-186', 'respect-gbm', 'gbm']
phase 1 findings from the respect-gbm trial showed that rhenium-186 nanoliposome administered at doses exceeding 100 gy elicited promising safety and efficacy results in patients with recurrent glioma. #esmo2022 | 
Oncology news and insights from leading researchers and cancer centers.